Premaitha Share Discussion Threads

[hjb1] 01/7/2018 16:21

he had a problem with wind didn't he? lol

[small crow] 01/7/2018 15:40

Hopefully not by Michael Fish?

[hjb1] 01/7/2018 13:14

yes, more good news,gonna be a hot summer for news I'm told.

[hjb1] 27/6/2018 09:51

From the news section of abnova.

[captain_kurt] 27/6/2018 09:43

From the news section of abnova.

hxxp://www.abnova.com/aboutus/news_detail.asp?CTID={FD47C71F-1EFF-42DB-A061-03D8E69C3876}

Neihu, Taiwan (June 26, 2018)

Abnova and Yourgene announced today to collaborate and accelerate next generation sequencing (NGS) capability for single cell analysis in Taiwan. Abnova has successfully developed a large portfolio of cell-based liquid biopsy technologies for enrichment and isolation of circulating tumor cell (CTC) and circulating fetal cell (CFC) technologies in recent years. Yourgene is one of the recognized world leaders of NGS analysis for both academic research and non-invasive prenatal testing/screening (NIPT, NIPS) and was successfully acquired by Premaitha Health, a public listed company in United Kingdom, last year. Both Abnova and Yourgene will work together to build the single cell NGS infrastructure for point mutation, insertion and deletion (INDEL), gene fusion, copy number variation (CNV), and chromosomal aneuploidies for the analysis of CTCs and CFCs. Both companies aim to efficiently integrate each other’s upstream and downstream capabilities to speed up single cell’s laboratory-developed test (LDT) and in vitro diagnostics (IVD) application and commercialization for the cancer and prenatal markets.

“Single cell analysis has gained increased importance in precision medicine, particularly for cancer and prenatal markets,” said Dr. Wilber Huang, President of Abnova Corporation. “On the cancer front, this is evidenced by tumor’s single cell heterogeneity which propels the physicians and patients to identify more tumor mutations, tumor burden, and RNA signature to improve drug guidance, particularly in the new era of immunotherapy. On the prenatal front, the renewed enthusiasm for fetal cell for prenatal diagnosis is propelled by the need to accurately identify microdeletions and non-X-linked monogenic diseases in the fetus. We look forward to working closely with Yourgene as our downstream NGS expert in this collaboration.”;

“We are excited to be working with Abnova which has developed end-to-end solutions for the upstream CTC and CFC enrichment, identification, and isolation,” said Dr. Bill Chang, President of Yourgene. “In the biotech community, collaboration is essential to spearhead the products into the market which rewards the first movers. Many companies have great technologies and innovations but the final commercialization is often hampered by critical factors which can be solved more quickly by open integration and collaboration. Moreover, we are also seeing the focus of NGS shifting from the academic research to clinical applications. This is an area of strength for Yourgene.”

[ngen yap] 27/6/2018 08:05

VERY strong and positive developments since my last post, with share price reacting accordingly. Will share more of my thoughts soon but on the partnership agreement yesterday, think it is not as far as some think. My read is that it is simply integating upstream (Abnova) and downstream (Yourgene) capabilities which are already there. So, it is a significant development and partnership into new offerings.

All the best. Ngen

[pj 1] 26/6/2018 15:57

hmmm fair comment hjb1, Id have to agree on that.

[hjb1] 26/6/2018 15:48

From RNS January, they did communicate.Reads to me that Illumina ain't interested!


'We have attempted to engage Illumina into meaningful settlement discussions both before and since the November judgment. We will continue to pursue such discussions as we believe these are firmly in the best interests of patients, clinicians, the NHS and the companies involved. We are open to terms that are financially viable for us to offer IONA® within the UK without the negative drag on the whole market that this litigation engenders'.

[pj 1] 26/6/2018 15:27

Then NIPT need to communicate that

[hjb1] 26/6/2018 15:25

If Illumina are not interested in a settlement (likely), then what??
It seems that it's not only Prem that think they have a chance on appeal otherwise they would not have been granted the right to try.

[pj 1] 26/6/2018 14:56

My main concern is that they still think that they can win as they feel hard done by, and have employed new Briefs to advise such (and no doubt line their own pockets)

They should bite the bullet, take it on the chin, settle and move on imo

[goforgold1] 26/6/2018 14:54

These developments are years away. All very early stage

[captain_kurt] 26/6/2018 14:44

Big news imo.

Move towards a lab test for cancer with a global partner

[twix386] 26/6/2018 14:31

More good news.Share price hardly moves as usual.Bod, please give us the illumina closure news. Settlement or come out of UK. Other news is good or even great, but I don't much care anymore. The news that will propel us is and has always been closure on our never ending fiasco of litigation!!!!!!

[timojelly] 26/6/2018 14:31

Get the monkey off our backs please.

[philjeans] 26/6/2018 13:58

RNS - More excellent news!


Collaboration with Abnova
Partnership to develop next generation sequencing capability for single cell analysis
Manchester, UK - 26 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, announces that it has entered into a partnership with Abnova, the world's largest monoclonal antibody manufacturer, to collaborate on the development of next generation sequencing ("NGS") capabilities for single cell analysis.
Abnova has successfully developed a large portfolio of cell-based liquid biopsy technologies, focused on the enrichment and isolation of circulating tumour cells ("CTC") and circulating fetal cells ("CFC"). Premaitha, through its Yourgene subsidiary, will work with Abnova in Taiwan to build the single cell NGS infrastructure for the analysis of CTCs and CFCs.
Premaitha and Abnova will work together in order to accelerate the adoption of a laboratory-developed single cell test by integrating their respective systems and developing the applications for in vitro diagnostics, as well as commercialising the test for the cancer and prenatal markets.
Dr Stephen Little, CEO of Premaitha, commented: "In biotechnology, collaboration is essential and we are thrilled to be partnering with a company of Abnova's calibre, who we believe have the complementary expertise to our Yourgene team to drive the development of NGS capabilities for single cell analysis. This partnership further evidences the continued progress we are making in extending our potential product range by leveraging our underlying technologies and developing key collaboration partnerships."

[thebigchap] 21/6/2018 06:56

steady men, can we get back on topic please

[small crow] 14/6/2018 16:14

err .... OK Trev.

[trev1223] 14/6/2018 15:43

small crow:
It is complimentary, however, a complement is a complement.

[dire cons] 14/6/2018 13:14

Many thanks for your in-depth reply.
=~)

[small crow] 13/6/2018 21:55

I'm sure it's complimentary but is it complementary?

[dire cons] 13/6/2018 10:25

Question. Does the tie-up with Coastal conflict with our partnership with Thermo, or is it meant to be complimentary?

[captain_kurt] 13/6/2018 07:23

Further good news today

'Premaitha wins 'Outstanding NIPS Solution Provider of the Year' award'

[viking01] 11/6/2018 18:12

Illumina exposure is such a small part of group turnover and I suspect overseas news flow will continue and share price respond accordingly . Great opportunity to participate in what will be a great growth story